Kodiak Sciences (KOD) Projected to Post Quarterly Earnings on Thursday

Kodiak Sciences (NASDAQ:KOD) is expected to be issuing its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect Kodiak Sciences to post earnings of ($1.02) per share for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, April 2, 2026 at 4:00 PM ET.

Kodiak Sciences Price Performance

Kodiak Sciences stock opened at $21.85 on Wednesday. Kodiak Sciences has a 1-year low of $1.92 and a 1-year high of $31.18. The business has a fifty day moving average price of $24.80 and a 200-day moving average price of $21.48. The stock has a market capitalization of $1.16 billion, a price-to-earnings ratio of -5.30 and a beta of 2.61.

Institutional Investors Weigh In On Kodiak Sciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Aster Capital Management DIFC Ltd purchased a new stake in shares of Kodiak Sciences in the fourth quarter worth about $119,000. BNP Paribas Financial Markets raised its position in Kodiak Sciences by 89.4% during the third quarter. BNP Paribas Financial Markets now owns 6,373 shares of the company’s stock valued at $104,000 after acquiring an additional 3,009 shares in the last quarter. Cibc World Market Inc. acquired a new position in Kodiak Sciences in the fourth quarter valued at approximately $206,000. Headlands Technologies LLC boosted its position in Kodiak Sciences by 256.4% in the 2nd quarter. Headlands Technologies LLC now owns 8,083 shares of the company’s stock worth $30,000 after purchasing an additional 5,815 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System acquired a new stake in shares of Kodiak Sciences during the 4th quarter worth approximately $272,000. 89.06% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. UBS Group assumed coverage on Kodiak Sciences in a research note on Wednesday, January 7th. They set a “buy” rating and a $50.00 price target on the stock. HC Wainwright reiterated a “buy” rating and issued a $38.00 target price on shares of Kodiak Sciences in a research note on Tuesday, February 10th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Kodiak Sciences in a research note on Thursday, January 22nd. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $28.29.

About Kodiak Sciences

Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company’s proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak’s research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.

The lead product candidate in Kodiak’s pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.